CINECA IRIS Institutional Research Information System

ANTONIOTTI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.246
AS - Asia 4.701
EU - Europa 2.712
SA - Sud America 850
AF - Africa 212
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.737
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.032
SG - Singapore 1.678
CN - Cina 1.007
IT - Italia 908
HK - Hong Kong 860
BR - Brasile 674
VN - Vietnam 469
DE - Germania 309
SE - Svezia 305
BG - Bulgaria 228
GB - Regno Unito 199
FR - Francia 190
IN - India 130
CA - Canada 124
RU - Federazione Russa 122
JP - Giappone 121
FI - Finlandia 115
TR - Turchia 72
BD - Bangladesh 68
AT - Austria 66
AR - Argentina 60
CI - Costa d'Avorio 58
NL - Olanda 55
KR - Corea 54
MX - Messico 43
UA - Ucraina 41
IQ - Iraq 38
PL - Polonia 38
ID - Indonesia 32
ZA - Sudafrica 31
EC - Ecuador 30
ES - Italia 28
UZ - Uzbekistan 25
NG - Nigeria 24
SN - Senegal 24
PH - Filippine 22
SA - Arabia Saudita 21
PK - Pakistan 20
VE - Venezuela 20
BE - Belgio 19
CZ - Repubblica Ceca 16
CO - Colombia 15
IE - Irlanda 15
PY - Paraguay 14
MA - Marocco 13
EG - Egitto 12
PE - Perù 12
CL - Cile 11
DZ - Algeria 11
TN - Tunisia 11
JM - Giamaica 9
LT - Lituania 9
UY - Uruguay 9
IL - Israele 8
KE - Kenya 8
AE - Emirati Arabi Uniti 7
PT - Portogallo 7
AZ - Azerbaigian 6
CH - Svizzera 6
JO - Giordania 6
MY - Malesia 6
NZ - Nuova Zelanda 6
PA - Panama 6
RO - Romania 6
BO - Bolivia 5
BY - Bielorussia 5
CR - Costa Rica 5
NO - Norvegia 5
OM - Oman 5
PS - Palestinian Territory 5
SY - Repubblica araba siriana 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AO - Angola 4
AU - Australia 4
BB - Barbados 4
ET - Etiopia 4
GT - Guatemala 4
LB - Libano 4
NI - Nicaragua 4
NP - Nepal 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
DK - Danimarca 3
GR - Grecia 3
KH - Cambogia 3
LK - Sri Lanka 3
LY - Libia 3
AM - Armenia 2
BF - Burkina Faso 2
BS - Bahamas 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
PR - Porto Rico 2
RS - Serbia 2
AI - Anguilla 1
BH - Bahrain 1
Totale 16.713
Salva come PNG Salva come JPEG
Città #
Singapore 931
Ashburn 870
Hong Kong 837
Woodbridge 761
Santa Clara 596
San Jose 538
Fairfield 536
Dallas 472
Chandler 470
Houston 416
Ann Arbor 401
Seattle 257
Shanghai 244
Sofia 228
Wilmington 210
New York 207
Cambridge 191
Beijing 179
Boardman 147
Los Angeles 142
Ho Chi Minh City 128
Milan 116
Princeton 112
Pisa 104
Lawrence 103
Tokyo 99
Lauterbourg 92
Medford 86
Hanoi 83
Florence 81
Hefei 81
London 77
Ottawa 74
Des Moines 69
Munich 68
Abidjan 58
Vienna 56
Council Bluffs 53
São Paulo 51
Buffalo 50
Dearborn 50
Seoul 49
Frankfurt am Main 47
Düsseldorf 44
Rome 42
Dong Ket 41
Cascina 40
Redondo Beach 40
Helsinki 39
Ogden 39
San Diego 38
Istanbul 37
Nanjing 34
Warsaw 33
Bremen 32
Turin 31
Chicago 30
Genoa 30
Turku 27
Dakar 24
Lagos 23
Rio de Janeiro 23
Phoenix 22
Redwood City 22
Serra 22
Nuremberg 21
Orem 20
Boulder 19
Haiphong 19
Montreal 19
Brussels 18
Tashkent 18
Kunming 17
Mumbai 17
Fuzhou 16
Baghdad 15
Da Nang 15
Guangzhou 15
Jacksonville 15
Atlanta 14
Dhaka 14
Izmir 14
Pune 14
Seacroft 14
Shenyang 14
Chennai 13
Dublin 13
Manchester 13
Toronto 13
Nanchang 12
San Francisco 12
Columbus 11
Johannesburg 11
Marseille 11
Quito 11
Stockholm 11
Belo Horizonte 10
Boston 10
Brasília 10
Guayaquil 10
Totale 11.632
Salva come PNG Salva come JPEG
Nome #
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 307
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 243
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 215
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 191
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 188
TAS-102 for the treatment of metastatic colorectal cancer 181
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 181
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 178
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 175
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 174
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 173
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 171
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 168
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 168
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 166
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 166
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 164
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 163
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 160
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 158
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 158
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 157
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 157
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 157
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 156
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 155
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 152
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 150
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 150
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 148
A still missing piece of the FIRE-3 puzzle 148
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 147
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 147
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 147
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 143
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 142
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 142
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 142
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer 141
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. 139
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 139
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. 138
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 138
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 136
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 136
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 135
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 134
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 134
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV). 130
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 130
Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. 129
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 129
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 128
Primary tumor location is a major independent prognostic factor for mcrc patients. 128
Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). 128
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 128
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 126
prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 126
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). 124
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 124
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. 124
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 123
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 123
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 122
FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. 122
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 121
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 120
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm 120
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 120
Ksr1 gene polymorphism in mcrc patients treated with first-line folfiri and bevacizumab. 119
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? 116
Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study 115
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 115
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 112
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 112
Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. 111
null 111
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. 111
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 111
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? 110
KSR1 gene polymorphism in MCRC patients treated with first-line folfiri and bevacizumab. 110
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 109
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 108
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 108
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. 106
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 102
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 102
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 99
The winding roadmap of biomarkers toward clinic: Lessons from predictors of resistance to anti-EGFRs in metastatic colorectal cancer 99
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 99
Prospective evaluation of candidate snps of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients treated with first-line folfiri plus bevacizumab (BV). 97
Totale 14.193
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021202 0 0 0 0 0 0 0 0 0 0 47 155
2021/2022972 25 24 23 18 162 171 18 32 54 72 72 301
2022/20231.422 170 193 88 126 138 200 15 86 235 23 131 17
2023/20241.193 75 96 202 81 146 178 98 45 27 39 85 121
2024/20254.248 86 139 70 179 397 488 320 193 422 504 427 1.023
2025/20265.233 372 623 587 543 514 431 736 361 366 502 198 0
Totale 17.060